Drug-induced phospholipidosis: are there functional consequences?
about
Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphilesDrug induced phospholipidosis: an acquired lysosomal storage disorderLysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitroLysosomal phospholipase A2 and phospholipidosisMorphometric Characterization of Rat and Human Alveolar Macrophage Cell Models and their Response to Amiodarone using High Content Image Analysis.Effect of phospholipidosis on the cellular pharmacokinetics of chloroquineIdentification of drugs inducing phospholipidosis by novel in vitro dataSimulation-based cheminformatic analysis of organelle-targeted molecules: lysosomotropic monobasic amines.Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver DiseaseNonesterified cholesterol content of lysosomes modulates susceptibility to oxidant-induced permeabilization.Mapping the cellular response to small molecules using chemogenomic fitness signatures.Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis.Breast cancer medications and vision: effects of treatments for early-stage disease.Successful drug development despite adverse preclinical findings part 2: examples.Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry diseaseFamilial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B InhibitorGroup XV phospholipase A₂, a lysosomal phospholipase A₂.Renal phospholipidosis possibly induced by ranolazine.Differential cytotoxicity responses by dog and rat hepatocytes to phospholipogenic treatments.A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury.One man's poison is another man's meat: using azithromycin-induced phospholipidosis to promote ocular surface health.The role of negatively charged lipids in lysosomal phospholipase A2 functionIntracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology.Amoxillin- and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues.Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies.Predicting the mechanism of phospholipidosis.Predicting phospholipidosis using machine learning.Hypolipidemic effects of lactic acid bacteria fermented cereal in ratsAlterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.
P2860
Q24685842-0E12F2C1-93FE-43F6-892D-CDA11E9BE18EQ26864959-B7BE79CB-21A3-4119-9CAD-00162A1F53B0Q28484924-5F9A2ADD-583A-414E-9FA1-80CDFC8DC714Q28584862-EE1EBD0C-0127-4C2A-BB5C-00C84F5FB423Q30313151-66A49279-BFB9-4B77-97D3-B0DAF1175555Q30498935-0FBE3F61-ABF8-4DBD-B2FB-F6532C14F54BQ30560958-52E1C422-1966-4A64-8B93-8BD2BAAA54E9Q33323615-C1CC625F-E9BC-4C5D-801D-0A4C91B5A8EAQ33667541-7CB8B117-FF15-49FA-90B4-4AE8EDF6ED58Q33734125-C579E839-376E-4224-BAD7-27858D848009Q34478831-3A7DC3DB-A472-41EC-9F05-6E5A9234681AQ34626429-C4A4D1B8-76F1-4445-BF26-737EF7EEED75Q34736225-6A316B26-4E05-4309-BB4B-4C4B27B0119CQ35496778-7A50D740-515F-4135-9150-73B72BA07F61Q35603965-92D0827F-1C67-44E5-BC8A-8CC5BA4C01E7Q35691719-3263B6F7-0BF8-409F-8194-80260B929A88Q35806445-BF309C1C-5A22-441B-99A9-864BCD7C0A1DQ35846845-32E0E893-0CAE-41EE-83F5-F70A388C5543Q35981136-743F0231-B591-46F1-AD16-E2615F707BC0Q36012553-D62CEAD8-ECF9-462C-B6C8-520D7B5E83C3Q36018942-2DCA1671-112B-4294-957A-F7D375DB35F5Q37251993-9775C0D2-8CEC-4B74-BBCD-C76B66BFCDC0Q37723945-6194A8A8-768A-4C46-8D2C-B689197E1900Q37809218-CE4C785C-1C60-4C3E-A1B6-C936AE17A7D6Q39369271-DF084E36-178A-4F87-BEBE-CE1C191EFFEEQ39374963-B15EE035-1F0B-4537-94A1-3164E2A6D6CAQ39707536-7FDD4607-6905-4EB4-9DC6-EB158F86D364Q39738019-54D76345-E92C-42C8-BFF6-39E0AC33E4BBQ41884835-29C4491E-2746-4CFF-AB0E-0AA5624BA470Q41973216-2A5F77DA-BB9C-4292-A337-2B2B290A7FB6Q42145880-29EB5DF9-4AAD-4513-A71C-0E80B03E741BQ42213351-6A5B272E-4C9C-4B9A-A356-E1B491C3EA56Q42239181-88912753-21DA-4118-9FC7-83D82D994456Q42414848-450683B7-6A14-4012-84C4-863419975B4BQ42822476-FA90F731-2313-48F4-9A14-A0057FF17659Q48320658-37A5E8FD-15DB-44E0-8B33-C86DBD2C2F1DQ49923423-ACF996EE-94AF-47EF-85D9-B4EAD19071D2Q55497000-D5FB95BA-C8EF-46F0-A705-DDDD8F676BBC
P2860
Drug-induced phospholipidosis: are there functional consequences?
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Drug-induced phospholipidosis: are there functional consequences?
@ast
Drug-induced phospholipidosis: are there functional consequences?
@en
Drug-induced phospholipidosis: are there functional consequences?
@nl
type
label
Drug-induced phospholipidosis: are there functional consequences?
@ast
Drug-induced phospholipidosis: are there functional consequences?
@en
Drug-induced phospholipidosis: are there functional consequences?
@nl
prefLabel
Drug-induced phospholipidosis: are there functional consequences?
@ast
Drug-induced phospholipidosis: are there functional consequences?
@en
Drug-induced phospholipidosis: are there functional consequences?
@nl
P1476
Drug-induced phospholipidosis: are there functional consequences?
@en
P2093
P304
P577
2001-10-01T00:00:00Z